Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) ...

Nearly half of individuals consuming alcohol at baseline reduced their alcohol consumption following the initiation of AOMs.

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without ...

The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity ...

The medication’s primary mechanism involves mimicking glucagon-like peptide-1 (GLP-1), a naturally occurring hormone in the ...

There is some debate as to whether GLP-1 agonist drugs like Wegovy can lead to unhealthy muscle mass loss in addition to ...

A SYSTEMATIC review investigating the impact of glucagon-like peptide-1 receptor agonists on alcohol consumption has yielded ...

Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...

Clinicians are advised to screen patients for conditions that would have rendered them ineligible to participate in the ...

The drugs in question are known to scientists as GLP-1 agonists — so named because they imitate glucagon-like peptide-1, a ...

The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) ...